PDCD1 and vitiligo: In this review, among the studies that identified vitiligo as an irAE [27,33,40–43,49,50,52,57,58,60–62], the majority of them evaluated patients treated with anti-PD-1 as a monotherapy or in combination therapy [33,40–43,49,50,57,58,60–62].